



Press Release

October 31st, 2025

SONIRE Therapeutics Inc.

SONIRE Therapeutics Announces Publication of Joint Research Results with Tokyo University of Pharmacy and Life Sciences

SONIRE Therapeutics Co., Ltd. (Head Office: Chuo-ku, Tokyo; President & CEO: Tohru Satoh; hereinafter "the Company") is pleased to announce that the results of its joint research with Tokyo University of Pharmacy and Life Sciences have been published in a peer-reviewed academic journal. This research was conducted in collaboration with Associate Professor Rui Tada of the Laboratory for Immunopharmacology of Microbial Products and Professor Yoichi Negishi of the Laboratory of Drug Delivery and Molecular Biopharmaceutics, School of Pharmacy, Tokyo University of Pharmacy and Life Sciences.

Publication Details

Title: Cavitation bubble-assisted high-intensity focused ultrasound induces abscopal immune responses

Journal: International Immunopharmacology

Article URL: <https://www.sciencedirect.com/science/article/pii/S1567576925015565>

In this study, Trigger HIFU for a small-animal model based on the same principle as SONIRE's HIFU therapy system (development code: Suizenji) was used to evaluate the immune-stimulating effects of HIFU on tumors. Trigger HIFU was applied only to the right-side tumor in mice bearing tumors on both flanks, a significant suppression of tumor growth was also observed in the untreated left-side tumor. Detailed mechanistic analyses revealed an increase in tumor-infiltrating cytotoxic T cells, demonstrating that Trigger HIFU activates CD8⁺ T cell-dependent anti-tumor immunity and may exert systemic effects even on distant metastatic lesions.

SONIRE will continue to promote our business in order to realize the wish we put in our company name at the time of our foundation: *"Sonics brings a hopeful new future to as many cancer patients and their families as possible."*